Approval · Notice of Compliance 2296 · 2001
PMS-GABAPENTIN: Notice of Compliance 2296
Issued February 23, 2001
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 2296
- Date
- February 23, 2001
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-GABAPENTIN | 02243446 | Marketed |
| PMS-GABAPENTIN | 02243447 | Marketed |
| PMS-GABAPENTIN | 02243448 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP